Forskningsradar

Science Journals

Peer-reviewade publikationer — 350 artiklar

What to Know About the Cicada SARS-CoV-2 Variant
This JAMA Medical News article discusses the unusual trajectory of BA.3.2, the most recent version of SARS-CoV-2 to be designated a Variant Under Monitoring by the World Health Organization.
WHO Releases New Tuberculosis Testing Guidelines
The World Health Organization (WHO) released new guidelines on tests for tuberculosis, encouraging the use of portable diagnostics, pooling of sputum samples, and tongue swabs.
Long-Term Neurocognitive Outcomes After Severe Malaria Infection
In 1948, Salil Ghosh wrote of the near-miraculous recovery of several children with severe “malignant malaria” who had been treated with quinine. One illustrative patient, a “girl aged 9 years,” was admitted with 2 days of “unconsciousness with delirium” and found to have “rings plenty,” the classic finding of blood-stage Plasmodium falciparum infection seen on peripheral blood smear. Following administration of intramuscular, and then oral, quinine, the patient “went home in perfect health.”
A Love Letter to Clinical Trials
Trials come with a multitude of tribulations. Funding for clinical trials can be elusive. Regulatory hurdles are many. Participants are hard to recruit and sometimes even harder to retain. Protocols can be unwieldy, and trial timelines can stretch endlessly. And even when completed, trials can yield results that defy expectations and challenge interpretation. As former National Institutes of Health Director Donald Fredrickson remarked more than 60 years ago, trials “strain our resources and patience, and they protract the moment of truth to excruciating limits.” And yet, clinical trials remain the bedrock of evidence-based medicine—and perhaps always will. When the stakes are highest, the medical community looks to trials to provide the certainty—or at least the clarity—needed to act.
Inconsistencies Between Text and Table
In the US Preventive Services Task Force Recommendation Statement titled “Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality,” published in the September 28, 2021, issue of JAMA, there were inconsistencies between Table 1 and the Practice Considerations section. Table 1 incorrectly stated, “Recommend low-dose aspirin if the patient has ≥2 moderate-risk factors. Consider low-dose aspirin if the patient has 1 of these moderate-risk factors.” Table 1 has been updated to accurately state, “Pregnant persons with 2 or more moderate-risk factors may also benefit from low-dose aspirin.” The Recognition of Risk Status section was also updated to list specific moderate risk factors more clearly and to fully align with those risk factors named in Table 1. This article was corrected online.
More US Immigration Detention, Less Oversight, and More Deaths
When a government detains a person, it assumes a duty of care. That person’s health—and survival—depends on whether the detaining authority provides adequate care, maintains health-promoting conditions, and responds to medical needs. Mortality in detention is thus a sentinel measure of whether the state is meeting its custodial obligation to provide humane conditions and adequate medical care, an obligation grounded in constitutional due process principles, domestic detention standards, and international human rights norms.
Mandatory Training Modules in Health Care
This Viewpoint discusses the financial and opportunity costs of mandatory health care training modules and how a reassessment based on adult learning theory could improve patient safety and professional growth while reducing burnout.
Incorrect Data and Reference
In the US Preventive Services Task Force Recommendation Statement titled “Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement,” published in the June 11, 2024, issue of JAMA, a relative risk reduction and its supporting reference incorrectly reflected earlier data. On page 1923, in the “Benefits and Comparative Benefits of Early Detection and Treatment” section, the relative risk reduction reported as 0.88 (95% CI, 0.73-1.00; 9 trials) should have read 0.92 (95% CI, 0.75-1.02; 9 trials). In the reference list, reference 44 should have read Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 US Preventive Services Task Force recommendation. Ann Intern Med. 2016;164(4):244-255. doi:10.7326/M15-0969. This article was corrected online.
Virtual and Remotely Conducted Trials
Virtual and remote trials represent a critical shift in how interventional research is conducted, with participants engaging in clinical trials from where they live or work rather than making repeated visits to brick-and-mortar research sites. Leveraging the increasingly widespread use of smartphones, personal computers, and the internet—all accelerated during the COVID-19 pandemic—decentralized trials relying on digital tools to engage participants remotely have proliferated rapidly. Institutional review boards now permit completely remote informed consent, based on digitally delivered information rather than face-to-face contact between participants and study personnel. Study medications, investigational devices, and biospecimen collection materials can be shipped directly to participants’ homes instead of being distributed during in-person study visits. Smartphone and other mobile devices are used to collect patient-reported data in real time, capturing symptom and quality-of-life patterns as participants experience them in their everyday lives. Wearable sensors and connected devices can also continuously monitor participants’ vital signs, physical activity, and other physiological parameters in their usual living environments, generating longitudinal data streams in place of intermittent study clinic-based measurements.
“Hooch,” “Home Brew” and Copper
The toxicity of many of the heavy metals has been known for generations, yet these substances have not been regarded as a menace to human health except in limited instances where industrial conditions or occupational circumstances exposed workers to the chemical hazards in some uncommon way. However much the student of vocational diseases might become concerned with the effects of metallic poisons, the treatises on public health and personal hygiene rarely discuss them except in a casual manner. As a consequence of modern economic and social changes, the latent dangers of poisoning from certain heavy metals are now suddenly presented to the public at large. To gasoline and the automobile we owe the nation-wide concern about lead; suicides and syphilis have awakened a new interest in mercury not merely as a drug but also as a poison; and now the advent of the “bootlegger” and home brew has brought copper to our toxicologic attention.
Prevention of Respiratory Syncytial Virus–Related Hospitalization in Newborns
To the Editor A recent article compared the real-world effectiveness of the 2 available immunization strategies against respiratory syncytial virus (RSV): passive infant immunization with the long-acting monoclonal antibody nirsevimab vs maternal vaccination with the RSV prefusion F protein (RSVpreF) vaccine. Nirsevimab was associated with lower risk of RSV-related hospitalization, admission to the pediatric intensive care unit, need for ventilatory support, and oxygen treatment. Nonetheless, we believe caution is warranted before drawing conclusions about the superiority of either strategy.
Smoking Cessation Intervention for People With Tuberculosis
To the Editor A recent study reported that a tuberculosis (TB)-specific mobile health text-messaging program delivered during TB treatment increased biochemically verified continuous abstinence at 6 months in Bangladesh and Pakistan and was associated with lower mortality. Tobacco cessation during TB care is a major, practical priority, and this trial provides encouraging evidence for scalable support.
The Art of Poetry, in Medicine
The great classical poet Horace wrote “Ars Poetica” around 19 BCE, his famous poem that uses the techniques of poetry itself to describe what poetry is and how it functions. Most memorably, perhaps, he declares that poetry must both “delight and instruct.” Since then, many poets have written their own versions of “Ars Poetica,” offering their own meditations regarding poetry as an art form. In this venerable and contentious tradition we can locate “Ars Poetica Medica,” which grapples with the possibilities of an art of medical poetry. Notably, echoing Horace, the poem’s diction is frankly didactic, with clear instructions like “First, step back/from the body.” Yet the poem also delights, perhaps unexpectedly given medicine’s distancing and diseases, with beautiful moments like “If meaning is the poem’s breath/then form is bone to brace the chest.” Thus the speaker proves medical poetry worthy of not just Horace’s definition of poetic art, but also of later poets, who, like the US physician-poet William Carlos Williams, insisted poetry must see our amazing world as it truly is. The speaker quotes “No ideas but in things,” Williams’ familiar admonition that poetry resist lofty notions of art and instead witness what is right before us (as he indelibly saw a hungry elderly woman savoring plums or a red wheelbarrow glistening in the rain). The poem’s final couplet affirms what medical poetry’s unflinching gaze reveals is authentically poetry—“To build a frame with words/to hold what words can’t say.”—that delights and instructs, yes, but also never looks away.
Screening for Breast Cancer
To the Editor The prevailing one-size-fits-all paradigm of breast cancer screening—largely based on age and fixed intervals—was designed during an era with limited risk stratification, few prevention pathways, and limited ability to tailor imaging intensity. Pragmatic randomized clinical trials, such as WISDOM, are therefore essential to generate evidence with a prevention strategy that can reallocate resources from women at lower risk of breast cancer to those at higher risk.
Screening for Breast Cancer
To the Editor Individualized, risk-based approaches to cancer screening aspire to resolve shortcomings of the traditional population- and age-based approach. Yet, until now, reliable evidence was not available to appropriately evaluate whether tailoring breast cancer screening according to cancer risk can increase benefits and reduce harms compared with the current approach. We therefore commend the WISDOM (Women Informed to Screen Depending on Measures of Risk) study, which provided crucial insights into risk-based breast cancer screening’s effects. However, we are concerned about the limited potential of risk-based screening for reducing harms, notably overdiagnosis, which involves diagnosis of cancers that do not progress to become symptomatic or harmful.